|
Bibliografía
1. Cotterill, S.J., Pearson, A.D., Pritchard, J., Foot, A.B., Roald, B., Kohler, J.A. and Imeson, J. (2000) Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group 'Survey' 1982-1992. Eur J Cancer, 36, 901-8.
2. Evans, A.E., Silber, J.H., Shpilsky, A. and D'Angio, G.J. (1996) Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution. J Clin Oncol, 14, 2504-10.
3. Brodeur, G.M., Pritchard, J., Berthold, F., Carlsen, N.L., Castel, V., Castelberry, R.P., De Bernardi, B., Evans, A.E., Favrot, M., Hedborg, F. and et al. (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol, 11, 1466-77.
4. Chatten, J., Shimada, H., Sather, H.N., Wong, K.Y., Siegel, S.E. and Hammond, G.D. (1988) Prognostic value of histopathology in advanced neuroblastoma: a report from the Childrens Cancer Study Group. Hum Pathol, 19, 1187-98.
5. Joshi, V.V., Rao, P.V., Cantor, A.B., Altshuler, G., Shuster, J.J. and Castleberry, R.P. (1996) Modified histologic grading of neuroblastomas by replacement of mitotic rate with mitosis karyorrhexis index. A clinicopathologic study of 223 cases from the Pediatric Oncology Group. Cancer, 77, 1582-8.
6. Shimada, H., Stram, D.O., Chatten, J., Joshi, V.V., Hachitanda, Y., Brodeur, G.M., Lukens, J.N., Matthay, K.K. and Seeger, R.C. (1995) Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst, 87, 1470-6.
7. Shimada, H., Chatten, J., Newton, W.A., Jr., Sachs, N., Hamoudi, A.B., Chiba, T., Marsden, H.B. and Misugi, K. (1984) Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst, 73, 405-16.
8. Shimada, H., Umehara, S., Monobe, Y., Hachitanda, Y., Nakagawa, A., Goto, S., Gerbing, R.B., Stram, D.O., Lukens, J.N. and Matthay, K.K. (2001) International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer, 92, 2451-61.
9. Shimada, H., Ambros, I.M., Dehner, L.P., Hata, J., Joshi, V.V., Roald, B., Stram, D.O., Gerbing, R.B., Lukens, J.N., Matthay, K.K. and Castleberry, R.P. (1999) The International Neuroblastoma Pathology Classification (the Shimada system). Cancer, 86, 364-72.
10. Cox, D., Yuncken, C. and Spriggs, A.I. (1965) Minute Chromatin Bodies in Malignant Tumours of Childhood. Lancet, 62, 55-8.
11. Brodeur, G.M., Sekhon, G. and Goldstein, M.N. (1977) Chromosomal aberrations in human neuroblastomas. Cancer, 40, 2256-63.
12. Schwab, M., Alitalo, K., Klempnauer, K.H., Varmus, H.E., Bishop, J.M., Gilbert, F., Brodeur, G., Goldstein, M. and Trent, J. (1983) Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature, 305, 245-8.
13. Gilbert, F., Feder, M., Balaban, G., Brangman, D., Lurie, D.K., Podolsky, R., Rinaldt, V., Vinikoor, N. and Weisband, J. (1984) Human neuroblastomas and abnormalities of chromosomes 1 and 17. Cancer Res, 44, 5444-9.
14. Maris, J.M. and Matthay, K.K. (1999) Molecular biology of neuroblastoma. J Clin Oncol, 17, 2264-79.
15. Hayashi, Y., Habu, Y., Fujii, Y., Hanada, R. and Yamamoto, K. (1986) Chromosome abnormalities in neuroblastomas found by VMA mass screening. Cancer Genet Cytogenet, 22, 363-4.
16. Look, A.T., Hayes, F.A., Nitschke, R., McWilliams, N.B. and Green, A.A. (1984) Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med, 311, 231-5.
17. Brodeur, G.M., Seeger, R.C., Schwab, M., Varmus, H.E. and Bishop, J.M. (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science, 224, 1121-4.
18. Tsuda, T., Obara, M., Hirano, H., Gotoh, S., Kubomura, S., Higashi, K., Kuroiwa, A., Nakagawara, A., Nagahara, N. and Shimizu, K. (1987) Analysis of N-myc amplification in relation to disease stage and histologic types in human neuroblastomas. Cancer, 60, 820-6.
19. Christiansen, H., Sahin, K., Berthold, F., Hero, B., Terpe, H.J. and Lampert, F. (1995) Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma. Eur J Cancer, 31A, 541-4.
20. Christiansen, H. and Lampert, F. (1988) Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma. Br J Cancer, 57, 121-6.
21. Maris, J.M., White, P.S., Beltinger, C.P., Sulman, E.P., Castleberry, R.P., Shuster, J.J., Look, A.T. and Brodeur, G.M. (1995) Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res, 55, 4664-9.
22. Caron, H., van Sluis, P., de Kraker, J., Bokkerink, J., Egeler, M., Laureys, G., Slater, R., Westerveld, A., Voute, P.A. and Versteeg, R. (1996) Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med, 334, 225-30.
23. Plantaz, D., Mohapatra, G., Matthay, K.K., Pellarin, M., Seeger, R.C. and Feuerstein, B.G. (1997) Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am J Pathol, 150, 81-9.
24. Brinkschmidt, C., Christiansen, H., Terpe, H.J., Simon, R., Boecker, W., Lampert, F. and Stoerkel, S. (1997) Comparative genomic hybridization (CGH) analysis of neuroblastomas--an important methodological approach in paediatric tumour pathology. J Pathol, 181, 394-400.
25. Vandesompele, J., Van Roy, N., Van Gele, M., Laureys, G., Ambros, P., Heimann, P., Devalck, C., Schuuring, E., Brock, P., Otten, J., Gyselinck, J., De Paepe, A. and Speleman, F. (1998) Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes Cancer, 23, 141-52.
26. Bown, N., Cotterill, S., Lastowska, M., O'Neill, S., Pearson, A.D., Plantaz, D., Meddeb, M., Danglot, G., Brinkschmidt, C., Christiansen, H., Laureys, G., Speleman, F., Nicholson, J., Bernheim, A., Betts, D.R., Vandesompele, J. and Van Roy, N. (1999) Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med, 340, 1954-61.
27. Janoueix-Lerosey, I., Penther, D., Thioux, M., de Cremoux, P., Derre, J., Ambros, P., Vielh, P., Benard, J., Aurias, A. and Delattre, O. (2000) Molecular analysis of chromosome arm 17q gain in neuroblastoma. Genes Chromosomes Cancer, 28, 276-84.
28. Cunsolo, C.L., Bicocchi, M.P., Petti, A.R. and Tonini, G.P. (2000) Numerical and structural aberrations in advanced neuroblastoma tumours by CGH analysis; survival correlates with chromosome 17 status. Br J Cancer, 83, 1295-300.
29. Vandesompele, J., Baudis, M., De Preter, K., Van Roy, N., Ambros, P., Bown, N., Brinkschmidt, C., Christiansen, H., Combaret, V., Lastowska, M., Nicholson, J., O'Meara, A., Plantaz, D., Stallings, R., Brichard, B., Van den Broecke, C., De Bie, S., De Paepe, A., Laureys, G. and Speleman, F. (2005) Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol, 23, 2280-99.
30. Takita, J., Hayashi, Y., Kohno, T., Shiseki, M., Yamaguchi, N., Hanada, R., Yamamoto, K. and Yokota, J. (1995) Allelotype of neuroblastoma. Oncogene, 11, 1829-34.
31. Ejeskar, K., Aburatani, H., Abrahamsson, J., Kogner, P. and Martinsson, T. (1998) Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene. Br J Cancer, 77, 1787-91.
32. Guo, C., White, P.S., Weiss, M.J., Hogarty, M.D., Thompson, P.M., Stram, D.O., Gerbing, R., Matthay, K.K., Seeger, R.C., Brodeur, G.M. and Maris, J.M. (1999) Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene, 18, 4948-57.
33. Luttikhuis, M.E., Powell, J.E., Rees, S.A., Genus, T., Chughtai, S., Ramani, P., Mann, J.R. and McConville, C.M. (2001) Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis. Br J Cancer, 85, 531-7.
34. Westermann, F. and Schwab, M. (2002) Genetic parameters of neuroblastomas. Cancer Lett, 184, 127-47.
35. Maris, J.M., Weiss, M.J., Guo, C., Gerbing, R.B., Stram, D.O., White, P.S., Hogarty, M.D., Sulman, E.P., Thompson, P.M., Lukens, J.N., Matthay, K.K., Seeger, R.C. and Brodeur, G.M. (2000) Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J Clin Oncol, 18, 1888-99.
36. Schwab, M., Westermann, F., Hero, B. and Berthold, F. (2003) Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol, 4, 472-80.
37. Brodeur, G.M. (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer, 3, 203-16.
38. Castel, V., Canete, A., Navarro, S., Garcia-Miguel, P., Melero, C., Acha, T., Navajas, A. and Badal, M.D. (2001) Outcome of high-risk neuroblastoma using a dose intensity approach: improvement in initial but not in long-term results. Med Pediatr Oncol, 37, 537-42.
39. Kaneko, M., Tsuchida, Y., Mugishima, H., Ohnuma, N., Yamamoto, K., Kawa, K., Iwafuchi, M., Sawada, T. and Suita, S. (2002) Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol, 24, 613-21.
40. Castel, V., Canete, A., Noguera, R., Navarro, S. and Oltra, S. (2005) [Neuroblastoma.]. Clin Transl Oncol, 7, 133-45.
41. Bocking, A., Giroud, F. and Reith, A. (1995) Consensus report of the European Society for Analytical Cellular Pathology task force on standardization of diagnostic DNA image cytometry. Anal Quant Cytol Histol, 17, 1-7.
42. Navarro, S., Noguera, R., Pellin, A., Mejia, C., Ruiz, A. and Llombart-Bosch, A. (2000) Pleomorphic anaplastic neuroblastoma. Med Pediatr Oncol, 35, 498-502.
43. Noguera, R., Canete, A., Pellin, A., Ruiz, A., Tasso, M., Navarro, S., Castel, V. and Llombart-Bosch, A. (2003) MYCN gain and MYCN amplification in a stage 4S neuroblastoma. Cancer Genet Cytogenet, 140, 157-61.
44. Kallioniemi, O.P., Kallioniemi, A., Piper, J., Isola, J., Waldman, F.M., Gray, J.W. and Pinkel, D. (1994) Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer, 10, 231-43.
45. Kallioniemi, A., Kallioniemi, O.P., Sudar, D., Rutovitz, D., Gray, J.W., Waldman, F. and Pinkel, D. (1992) Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science, 258, 818-21.
46. Lastowska, M., Nacheva, E., McGuckin, A., Curtis, A., Grace, C., Pearson, A. and Bown, N. (1997) Comparative genomic hybridization study of primary neuroblastoma tumors. United Kingdom Children's Cancer Study Group. Genes Chromosomes Cancer, 18, 162-9.
47. Breen, C.J., O'Meara, A., McDermott, M., Mullarkey, M. and Stallings, R.L. (2000) Coordinate deletion of chromosome 3p and 11q in neuroblastoma detected by comparative genomic hybridization. Cancer Genet Cytogenet, 120, 44-9.
48. Plantaz, D., Vandesompele, J., Van Roy, N., Lastowska, M., Bown, N., Combaret, V., Favrot, M.C., Delattre, O., Michon, J., Benard, J., Hartmann, O., Nicholson, J.C., Ross, F.M., Brinkschmidt, C., Laureys, G., Caron, H., Matthay, K.K., Feuerstein, B.G. and Speleman, F. (2001) Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer, 91, 680-6.
49. Lastowska, M., Cullinane, C., Variend, S., Cotterill, S., Bown, N., O'Neill, S., Mazzocco, K., Roberts, P., Nicholson, J., Ellershaw, C., Pearson, A.D. and Jackson, M.S. (2001) Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J Clin Oncol, 19, 3080-90.
50. Schleiermacher, G., Janoueix-Lerosey, I., Combaret, V., Derre, J., Couturier, J., Aurias, A. and Delattre, O. (2003) Combined 24-color karyotyping and comparative genomic hybridization analysis indicates predominant rearrangements of early replicating chromosome regions in neuroblastoma. Cancer Genet Cytogenet, 141, 32-42.
51. Guo, C., White, P.S., Hogarty, M.D., Brodeur, G.M., Gerbing, R., Stram, D.O. and Maris, J.M. (2000) Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas. Med Pediatr Oncol, 35, 544-6.
52. Spitz, R., Hero, B., Ernestus, K. and Berthold, F. (2003) FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma. Med Pediatr Oncol, 41, 30-5.
53. McArdle, L., McDermott, M., Purcell, R., Grehan, D., O'Meara, A., Breatnach, F., Catchpoole, D., Culhane, A.C., Jeffery, I., Gallagher, W.M. and Stallings, R.L. (2004) Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q. Carcinogenesis, 25, 1599-609.
54. Scaruffi, P., Valent, A., Schramm, A., Astrahantseff, K., Eggert, A. and Tonini, G.P. (2005) Application of microarray-based technology to neuroblastoma. Cancer Lett, 228, 13-20.
|